Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Sep;30(3):485–490. doi: 10.1128/aac.30.3.485

Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency.

D R Guay, R C Meatherall, G K Harding, G R Brown
PMCID: PMC180585  PMID: 3777912

Abstract

The pharmacokinetics of the extended-half-life, broad-spectrum oral cephalosporin cefixime (CL 284,635; FK 027) were studied in 7 healthy volunteers and 35 patients with various degrees of renal insufficiency, including patients undergoing continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis. Apparent total body, renal, and apparent nondialysis-nonrenal clearances and protein binding declined and elimination half-life increased with decreasing creatinine clearance. All of these alterations became statistically significant as the creatinine clearance fell below 20 ml/min per 1.73 m2. Cefixime concentrations in urine exceeded the MICs for most urinary tract pathogens for up to 24 h postdose, even in patients with severe renal insufficiency. CAPD removed an insignificant fraction of cefixime body burden over the 72-h study period (1.57 +/- 0.60% [mean +/- the standard error of the mean]). Area under the curve data suggested that hemodialysis similarly removed an insignificant fraction of the cefixime body burden. Volume of distribution at steady state was not altered significantly by renal insufficiency. It is recommended that standard doses of cefixime be administered at extended intervals, especially in patients with creatinine clearances less than 20 ml/min per 1.73 m2. In addition, supplemental doses are not necessary during CAPD and at the end of hemodialysis.

Full text

PDF
485

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benet L. Z., Galeazzi R. L. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci. 1979 Aug;68(8):1071–1074. doi: 10.1002/jps.2600680845. [DOI] [PubMed] [Google Scholar]
  2. Brittain D. C., Scully B. E., Hirose T., Neu H. C. The pharmacokinetic and bactericidal characteristics of oral cefixime. Clin Pharmacol Ther. 1985 Nov;38(5):590–594. doi: 10.1038/clpt.1985.229. [DOI] [PubMed] [Google Scholar]
  3. Gibson T. B., Nelson H. A. Drug kinetics and artificial kidneys. Clin Pharmacokinet. 1977 Nov-Dec;2(6):403–426. doi: 10.2165/00003088-197702060-00002. [DOI] [PubMed] [Google Scholar]
  4. Kamimura T., Kojo H., Matsumoto Y., Mine Y., Goto S., Kuwahara S. In vitro and in vivo antibacterial properties of FK 027, a new orally active cephem antibiotic. Antimicrob Agents Chemother. 1984 Jan;25(1):98–104. doi: 10.1128/aac.25.1.98. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Reidenberg M. M. The biotransformation of drugs in renal failure. Am J Med. 1977 Apr;62(4):482–485. doi: 10.1016/0002-9343(77)90401-6. [DOI] [PubMed] [Google Scholar]
  6. Shigi Y., Matsumoto Y., Kaizu M., Fujishita Y., Kojo H. Mechanism of action of the new orally active cephalosporin FK027. J Antibiot (Tokyo) 1984 Jul;37(7):790–796. doi: 10.7164/antibiotics.37.790. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES